VANCOUVER, British Columbia,
Jan. 13, 2022 /PRNewswire/ --Bold
Therapeutics, a clinical-stage biopharmaceutical company developing
BOLD-100, is pleased to announce an extension of the option
agreement with an undisclosed publicly traded South Korean
biopharmaceutical company, originally executed in May 2020, for development and commercialization
rights to BOLD-100 in South Korea.
The extension is expected to further solidify cooperation between
these companies, as well as support the addition of five clinical
trial sites in South Korea: Seoul
National University Hospital (PI:
Do-Youn Oh); Samsung Medical Center (PI: Joon Oh Park); Severance Hospital (PI:
Sun Young Rha); National Cancer
Center (PI: Yongjun Cha); and
Kangbuk Samsung Hospital (KBSMC) (PI: Dong-Hoe Koo).
Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based
small molecule therapeutic that (1) alters the unfolded protein
response (UPR) through selective GRP78 inhibition; and (2) induces
reactive oxygen species (ROS) which causes DNA damage and cell
cycle arrest. Collectively, these effects result in cell death in
both sensitive and resistant cancers, giving BOLD-100 the potential
to significantly improve outcomes in a wide range of both solid and
liquid tumors in combination with other anti-cancer therapies
ranging from traditional chemotherapies to targeted therapies to
immuno-oncology agents. BOLD-100 has been granted Orphan Drug
Designations (ODDs) by the FDA in both gastric (stomach) and
pancreatic cancers, and Bold Therapeutics expects to receive one or
more Breakthrough Therapy Designations (BTDs) for BOLD-100 in 2022.
Preclinical experiments have repeatedly shown that BOLD-100
improves outcomes in combination with a wide range of existing
anti-cancer therapies, with particular synergy evident in
drug-resistant cell lines.
"As our partner is one of the fastest growing and most respected
pharmaceutical companies in South
Korea, we are honored to extend this option agreement that
allows us to further leverage their substantial expertise in
oncology development," said E. Russell
McAllister, CEO of Bold Therapeutics. "We expect to complete
our Phase 1b trial of BOLD-100 in
combination with FOLFOX in the treatment of advanced
gastrointestinal cancers imminently and immediately transition into
a Phase 2a study at six sites in Canada, two sites in the U.S., and now five
sites in South Korea. We look
forward to continuing to work with our partner's team to advance
this revolutionary cancer therapy."
For more information about Bold Therapeutics, please visit the
company's website at www.bold-therapeutics.com
Media Contact:
E. Russell McAllister, CEO
327527@email4pr.com
(604) 262-9899
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bold-therapeutics-extends-south-korea-option-agreement-for-bold-100-a-first-in-class-anti-resistance-therapeutic-301460182.html
SOURCE Bold Therapeutics Inc.